Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 87 points (0.5%) at 16,606 as of Thursday, May 8, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,938 issues advancing vs. 1,065 declining with 159 unchanged. The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.5%. Top gainers within the industry include Biogen Idec ( BIIB), up 2.0%, Alexion Pharmaceuticals ( ALXN), up 1.5% and Regeneron Pharmaceuticals ( REGN), up 1.1%. On the negative front, top decliners within the industry include Merck ( MRK), down 1.3%, Valeant Pharmaceuticals International ( VRX), down 0.9%, Actavis ( ACT), down 0.9% and Allergan ( AGN), down 0.6%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Abbott Laboratories ( ABT) is one of the companies pushing the Drugs industry higher today. As of noon trading, Abbott Laboratories is up $0.21 (0.5%) to $38.90 on light volume. Thus far, 2.0 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.9 million shares. The stock has ranged in price between $38.55-$38.96 after having opened the day at $38.69 as compared to the previous trading day's close of $38.69. Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $59.5 billion and is part of the health care sector. Shares are up 0.9% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 7 rate it a hold. TheStreet Ratings rates Abbott Laboratories as a hold. Among the primary strengths of the company is its expanding profit margins over time. At the same time, however, we also find weaknesses including deteriorating net income and relatively poor performance when compared with the S&P 500 during the past year. Get the full Abbott Laboratories Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.